6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Currency in EUR

Valuation Measures

Market Cap (intraday) 51.73B
Enterprise Value 31.48B
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)64.97
Price/Book (mrq)9.70
Enterprise Value/Revenue 355.52
Enterprise Value/EBITDA 6-30.45

Trading Information

Stock Price History

Beta (5Y Monthly) -0.28
52-Week Change 322.45%
S&P500 52-Week Change 35.09%
52 Week High 358.93
52 Week Low 325.84
50-Day Moving Average 342.63
200-Day Moving Average 344.59

Share Statistics

Avg Vol (3 month) 35
Avg Vol (10 day) 3N/A
Shares Outstanding 538.54M
Float 10.96M
% Held by Insiders 166.33%
% Held by Institutions 132.46%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 31, 2019
Most Recent Quarter (mrq)Mar. 31, 2020


Profit Margin -183.30%
Operating Margin (ttm)-182.66%

Management Effectiveness

Return on Assets (ttm)-16.84%
Return on Equity (ttm)-30.66%

Income Statement

Revenue (ttm)26.69M
Revenue Per Share (ttm)0.72
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)24.19M
EBITDA -48.66M
Net Income Avi to Common (ttm)-48.93M
Diluted EPS (ttm)-1.32
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)196.52M
Total Cash Per Share (mrq)5.1
Total Debt (mrq)21.33M
Total Debt/Equity (mrq)12.20
Current Ratio (mrq)16.97
Book Value Per Share (mrq)4.54

Cash Flow Statement

Operating Cash Flow (ttm)-40.42M
Levered Free Cash Flow (ttm)-22.71M